ViCardia Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ViCardia Therapeutics is a private, clinical-stage biotech company targeting the significant unmet need in Acute Decompensated Heart Failure (ADHF), where no acute therapy has been shown to reduce mortality risk. The company's approach centers on correcting mitochondrial dysfunction, a fundamental driver of heart failure progression, using its lead compound GP531, a potent AMPK agonist. ViCardia is preparing to advance GP531 into Phase 2 clinical trials, aiming to restore myocardial bioenergetics and improve cardiac contractility. The company is led by a team with extensive cardiovascular research and development experience.

CardiovascularMetabolic DisordersNeurological Disorders

Technology Platform

Platform targeting mitochondrial dysfunction via AMPK activation to restore cellular bioenergetics, particularly in cardiac muscle.

Opportunities

The primary opportunity is addressing the massive unmet need in Acute Decompensated Heart Failure (ADHF), where no therapy has shown a mortality benefit.

A successful drug could capture a significant portion of the multi-billion dollar global heart failure market, driven by high hospitalization costs and a growing patient population.

Success would also validate the mitochondrial dysfunction platform for expansion into other indications like specific HFpEF, neurological, and metabolic disorders.

Risk Factors

The lead program carries high clinical risk, as targeting mitochondrial dysfunction in acute HF is a novel and unproven approach.

The company faces significant financing risk as a private, single-asset entity reliant on external capital.

It also operates in a highly competitive cardiovascular landscape dominated by large pharmaceutical companies with extensive resources.

Competitive Landscape

The competitive landscape for chronic heart failure is crowded with established therapies. However, the acute decompensated setting is less served, with current treatments focusing on symptom relief (diuretics, vasodilators) rather than mortality modification. ViCardia's primary competition may come from other companies investigating metabolic modulators or novel inotropes, but its specific AMPK/mitochondrial mechanism appears distinct from most late-stage candidates.

More companies in Small Molecule Drugs →More companies in United States →